$AEZS 1. Financially, this company is healthy with almost no debt. 2. It has an approved product and a successful phase II trial with a guidance into phase III, so this company is undervalued compared to its microcap biotech peers. 3. Usually, approving a product in the US by the FDA is very rigorous compared to other countries so Europe should be easier to deal with. It will find a partner in Europe to commercialize its product. 4. There are a lot warrants with exercize price of $0.45, $0.47, and $0.7041. Share price will get pumped at some point to collect the proceeds of these warrants (over $10M). 5. It's being traded in a very similar pattern to what I've seen in DFFN (from December 2019 to March 2020), and in ACHV (from April 2020 to July 2020), very boring and bearish pattern, but both have done well to patient investors. 6. I hate owning this stock.
  • 12